Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence

Roberta Piva, Flavia Ticconi, Valentina Ceriani, Federica Scalorbi, Francesco Fiz, Selene Capitanio, Matteo Bauckneht, Giuseppe Cittadini, Gianmario Sambuceti, Silvia Morbelli

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.

Original languageEnglish
Pages (from-to)461-471
Number of pages11
JournalBreast Cancer: Targets and Therapy
Volume9
DOIs
Publication statusPublished - Jul 4 2017

Fingerprint

Fluorodeoxyglucose F18
Breast Neoplasms
Recurrence
Magnetic Resonance Imaging
Sodium Fluoride
Patient Satisfaction
Bone and Bones
Survival
Positron Emission Tomography Computed Tomography

Keywords

  • Breast cancer
  • Positron emission tomography
  • Restaging

ASJC Scopus subject areas

  • Oncology

Cite this

Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence. / Piva, Roberta; Ticconi, Flavia; Ceriani, Valentina; Scalorbi, Federica; Fiz, Francesco; Capitanio, Selene; Bauckneht, Matteo; Cittadini, Giuseppe; Sambuceti, Gianmario; Morbelli, Silvia.

In: Breast Cancer: Targets and Therapy, Vol. 9, 04.07.2017, p. 461-471.

Research output: Contribution to journalReview article

Piva, R, Ticconi, F, Ceriani, V, Scalorbi, F, Fiz, F, Capitanio, S, Bauckneht, M, Cittadini, G, Sambuceti, G & Morbelli, S 2017, 'Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence', Breast Cancer: Targets and Therapy, vol. 9, pp. 461-471. https://doi.org/10.2147/BCTT.S111098
Piva, Roberta ; Ticconi, Flavia ; Ceriani, Valentina ; Scalorbi, Federica ; Fiz, Francesco ; Capitanio, Selene ; Bauckneht, Matteo ; Cittadini, Giuseppe ; Sambuceti, Gianmario ; Morbelli, Silvia. / Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence. In: Breast Cancer: Targets and Therapy. 2017 ; Vol. 9. pp. 461-471.
@article{0b3a878d4889454d96e76838b721d1bc,
title = "Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence",
abstract = "In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.",
keywords = "Breast cancer, Positron emission tomography, Restaging",
author = "Roberta Piva and Flavia Ticconi and Valentina Ceriani and Federica Scalorbi and Francesco Fiz and Selene Capitanio and Matteo Bauckneht and Giuseppe Cittadini and Gianmario Sambuceti and Silvia Morbelli",
year = "2017",
month = "7",
day = "4",
doi = "10.2147/BCTT.S111098",
language = "English",
volume = "9",
pages = "461--471",
journal = "Breast Cancer: Targets and Therapy",
issn = "1179-1314",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence

AU - Piva, Roberta

AU - Ticconi, Flavia

AU - Ceriani, Valentina

AU - Scalorbi, Federica

AU - Fiz, Francesco

AU - Capitanio, Selene

AU - Bauckneht, Matteo

AU - Cittadini, Giuseppe

AU - Sambuceti, Gianmario

AU - Morbelli, Silvia

PY - 2017/7/4

Y1 - 2017/7/4

N2 - In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.

AB - In the last decades, in addition to conventional imaging techniques and magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been shown to be relevant in the detection and management of breast cancer recurrence in doubtful cases in selected groups of patients. While there are no conclusive data indicating that imaging tests, including FDG PET/CT, produce a survival benefit in asymptomatic patients, FDG PET/CT can be useful for identifying the site of relapse when traditional imaging methods are equivocal or conflicting and for identifying or confirming isolated loco-regional relapse or isolated metastatic lesions. The present narrative review deals with the potential role of FDG PET in these clinical settings by comparing its accuracy and impact with conventional imaging modalities such as CT, ultrasound, bone scan, 18F-sodium fluoride PET/CT (18F-NaF PET/CT) as well as MRI. Patient-focused perspectives in terms of patients’ satisfaction and acceptability are also discussed.

KW - Breast cancer

KW - Positron emission tomography

KW - Restaging

UR - http://www.scopus.com/inward/record.url?scp=85024096832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024096832&partnerID=8YFLogxK

U2 - 10.2147/BCTT.S111098

DO - 10.2147/BCTT.S111098

M3 - Review article

AN - SCOPUS:85024096832

VL - 9

SP - 461

EP - 471

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

SN - 1179-1314

ER -